MCID: GST023
MIFTS: 53

Gastric Ulcer

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastric Ulcer

MalaCards integrated aliases for Gastric Ulcer:

Name: Gastric Ulcer 12 54 15 17 71 32
Acute Gastric Ulcer Without Mention of Hemorrhage or Perforation, Without Mention of Obstruction 12
Chronic Gastric Ulcer Without Hemorrhage and Without Perforation but with Obstruction 12
Chronic Gastric Ulcer Without Mention of Hemorrhage or Perforation, with Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Perforation, Without Mention of Obstruction 12
Acute Gastric Ulcer Without Hemorrhage, Without Perforation and Without Obstruction 12
Acute Gastric Ulcer with Hemorrhage and with Perforation but Without Obstruction 12
Acute Gastric Ulcer with Hemorrhage, with Perforation and with Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Perforation, with Obstruction 12
Chronic Gastric Ulcer Without Hemorrhage and Without Perforation 12
Acute Gastric Ulcer Without Hemorrhage and Without Perforation 12
Acute Gastric Ulcer with Perforation, with Obstruction 12
Acute Gastric Ulcer with Hemorrhage, with Obstruction 12
Acute Gastric Ulcer with Haemorrhage and Perforation 12
Acute Gastric Ulcer with Perforation and Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Obstruction 12
Acute Gastric Ulcer with Hemorrhage and Perforation 12
Acute Gastric Ulcer with Perforation 12
Bleeding Acute Gastric Ulcer 12
Gastric Ulcers 15
Stomach Ulcer 43

Classifications:



External Ids:

Disease Ontology 12 DOID:10808
ICD9CM 34 531
MeSH 43 D013276
NCIt 49 C3388
SNOMED-CT 67 6034002
ICD10 32 K25
UMLS 71 C0038358

Summaries for Gastric Ulcer

MalaCards based summary : Gastric Ulcer, also known as acute gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and hernia, hiatus. An important gene associated with Gastric Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Sodium citrate and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Gastric Ulcer

Diseases related to Gastric Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 792)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.4 S100A8 PTGS2 PTGS1 HRH2 GAST FGF2
2 hernia, hiatus 31.1 HRH2 GAST CYP2C19
3 helicobacter pylori infection 30.9 S100A8 IL1B GAST CYP2C19 CXCL8
4 peptic ulcer disease 30.6 TNF SST S100A8 PTGS2 PTGS1 IL1RN
5 peritonitis 30.6 TNF IL6 IL1B CXCL8
6 peptic ulcer perforation 30.6 S100A8 HRH2 GAST
7 bile reflux 30.4 TFF1 S100A8 PTGS2 GAST
8 zollinger-ellison syndrome 30.4 SST HRH2 GAST EGF
9 portal hypertension 30.3 VEGFA TNF SST CXCL8
10 hydrops, lactic acidosis, and sideroblastic anemia 30.3 VEGFA PTGS2 PTGS1
11 obstructive jaundice 30.2 TNF IL6 HGF CXCL8
12 cytomegalovirus infection 30.2 TNF IL6 IL1B CXCL8
13 systemic onset juvenile idiopathic arthritis 30.1 TNF IL1RN IL1B
14 crohn's colitis 30.1 TNF IL1B CXCL8
15 varicose veins 30.1 VEGFA TNF IL6 FGF2 CXCL8
16 pustulosis of palm and sole 30.0 TNF IL1RN CXCL8
17 candidiasis 30.0 TNF IL6 IL1B CXCL8
18 gastroduodenitis 30.0 S100A8 GAST
19 diverticulitis 30.0 TNF IL6 FGF2
20 graft-versus-host disease 30.0 TNF IL6 IL1B
21 rheumatic disease 29.9 TNF PTGS2 PTGS1 IL1RN IL1B
22 spondylitis 29.9 TNF IL6 IL1RN
23 gastritis 29.8 TNF SST S100A8 PTGS2 PTGS1 IL6
24 intussusception 29.8 VEGFA IL6 FGF2
25 colitis 29.8 TNF PTGS2 IL6 IL1B CXCL8
26 active peptic ulcer disease 29.8 SST PTGS2 PTGS1 HRH2 CYP2C19
27 myelitis 29.8 TNF IL6 CXCL8
28 systemic scleroderma 29.8 TNF IL6 HRH2 GAST
29 thyroiditis 29.7 TNF IL6 CALCA
30 bronchopneumonia 29.7 TNF IL6 CXCL8
31 toxic shock syndrome 29.7 TNF IL6 IL1RN IL1B CXCL8
32 typhoid fever 29.7 TNF IL6 IL1B
33 fatty liver disease 29.7 TNF IL6 IL1B CXCL8
34 exanthem 29.7 VEGFA TNF IL6 IL1RN CXCL8
35 ulcerative colitis 29.7 TNF IL6 IL1RN IL1B CXCL8
36 arteriovenous malformation 29.7 VEGFA TNF IL6
37 constipation 29.7 SST PTGS2 PTGS1 GAST CALCA
38 liver disease 29.6 TNF IL6 IL1B HGF CXCL8
39 tonsillitis 29.6 TNF IL6 IL1B CXCL8
40 celiac disease 1 29.6 TNF IL6 GAST CXCL8
41 acute pancreatitis 29.6 TNF SST IL6 IL1B CXCL8
42 cholangitis 29.6 TNF SST IL6 CXCL8
43 neuroendocrine tumor 29.6 VEGFA SST GAST CALCA
44 cholera 29.6 TNF IL6 EGF CXCL8
45 decubitus ulcer 29.6 VEGFA TNF IL6 FGF2
46 vaginitis 29.6 TNF IL6 IL1B CXCL8
47 inguinal hernia 29.5 PTGS2 IL6 HGF CALCA
48 gout 29.5 TNF IL6 IL1B CXCL8
49 dengue hemorrhagic fever 29.5 VEGFA TNF IL6 CXCL8
50 kaposi sarcoma 29.5 VEGFA IL6 FGF2 CXCL8

Graphical network of the top 20 diseases related to Gastric Ulcer:



Diseases related to Gastric Ulcer

Symptoms & Phenotypes for Gastric Ulcer

MGI Mouse Phenotypes related to Gastric Ulcer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 EPRS1 FGF2 GAST HRH2 IL1B IL1RN
2 hematopoietic system MP:0005397 10.11 FGF2 HGF IL1B IL1RN IL6 PSCA
3 digestive/alimentary MP:0005381 10.1 EGF GAST HRH2 IL6 PTGS1 PTGS2
4 immune system MP:0005387 10 EGF GAST IL1B IL1RN IL6 PSCA
5 integument MP:0010771 9.85 EGF EPRS1 IL1B IL1RN IL6 PSCA
6 neoplasm MP:0002006 9.65 FGF2 GAST IL1B IL6 PSCA PTGS1
7 skeleton MP:0005390 9.32 EPRS1 FGF2 IL1B IL1RN IL6 PTGS1

Drugs & Therapeutics for Gastric Ulcer

Drugs for Gastric Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Clarithromycin Approved Phase 4 81103-11-9 84029
4
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
5
Potassium citrate Approved, Investigational, Vet_approved Phase 4
6
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
7
Ofloxacin Approved Phase 4 82419-36-1 4583
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Magnesium oxide Approved Phase 4 1309-48-4 14792
10
Ibuprofen Approved Phase 4 15687-27-1 3672
11
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
12
Remifentanil Approved Phase 4 132875-61-7 60815
13
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Misoprostol Approved Phase 4 59122-46-2 5282381
16
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
17
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
18
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
20
Metronidazole Approved Phase 4 443-48-1 4173
21
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
24
Azithromycin Approved Phase 4 83905-01-5 55185 447043
25
Histamine Approved, Investigational Phase 4 51-45-6 774
26
Famotidine Approved Phase 4 76824-35-6 3325
27
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
28
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
29
Citalopram Approved Phase 4 59729-33-8 2771
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
31
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
32
Ecabet Investigational Phase 4 33159-27-2, 86408-72-2 65781
33 Rebamipide Investigational Phase 4 90098-04-7
34 Benzimidazole Experimental, Investigational Phase 4 51-17-2
35
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
36 Citrate Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Antipyretics Phase 4
39 Antioxidants Phase 4
40 Cytochrome P-450 CYP3A Inhibitors Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Geranylgeranylacetone Phase 4
43 Renal Agents Phase 4
44 Monoamine Oxidase Inhibitors Phase 4
45 Anti-Infective Agents, Urinary Phase 4
46 Anti-Infective Agents, Local Phase 4
47 Anticoagulants Phase 4
48 Calcium, Dietary Phase 4
49 Natriuretic Agents Phase 4
50 Expectorants Phase 4

Interventional clinical trials:

(show top 50) (show all 178)
# Name Status NCT ID Phase Drugs
1 Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial Unknown status NCT00926809 Phase 4 Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin;Lansoprazole (proton pump inhibitor), placebo
2 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
3 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
4 Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial Unknown status NCT01308177 Phase 4 Ecabet
5 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
6 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
8 A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy Completed NCT00233389 Phase 4 Rebamipide
9 A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed NCT00125736 Phase 4 E0671;rabeprazole sodium;E0671 placebo
10 An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours Completed NCT00428701 Phase 4 Esomeprazole Sodium
11 A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4 Selbex;Selbex
12 A Comparative Study on the Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy Completed NCT00272467 Phase 4 Rebamipide;Omeprazole
13 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy Completed NCT03609892 Phase 4 Berberine;Amoxicillin;Esomeprazole;Bismuth;Tetracycline;Furazolidone;Esomeprazole;Bismuth
14 Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
15 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study Completed NCT01135368 Phase 4 Lansoprazole
16 Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus. Completed NCT00476398 Phase 4
17 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
18 Double Blinded Randomized Placebo Controlled Study in Evaluating the Effectiveness of IV Acetaminophen for Acute Post Operative Pain in C-Section Patients Completed NCT02069184 Phase 4 IV Acetaminophen
19 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
20 Pain Management After Cardiac Surgery - Opioids or NSAID? A Randomized Prospective Study Completed NCT02479165 Phase 4 Ibuprofene;Oxycodone
21 Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil? Completed NCT01702389 Phase 4 Remifentanil
22 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
23 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
24 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
25 Dilapan vs Misoprostol for Cervical Ripening [COMRED - Comparison of Misoprostol Ripening Efficacy With Dilapan] Recruiting NCT03670836 Phase 4 Misoprostol
26 Efficacies of High-dose Dual Therapy With or Without Bismuth Versus Amoxicillin-metronidazole Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication - A Prospective, Randomized, Comparative Study Recruiting NCT03897244 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate);Amoxicillin-Metronidazole Bismuth quadruple therapy
27 Efficacy of Vaginal Misoprostol For Pain Relief During Office Hysteroscopy and Endometrial Biopsy; A Double Blind Randomized Controlled Trial Recruiting NCT03547778 Phase 4 Misoprostol 50 mcg pesssary;Placebos
28 Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy - a Randomized, Double-blind, Placebo-controlled Trial Recruiting NCT03783182 Phase 4 Betamethason Sodium Phosphate;10% glucose solution
29 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Active, not recruiting NCT02490839 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
30 Effect of Adding Azithromycin to Dexamethasone in Preventing Post-operative Nausea and Vomiting in Caesarean Section Under Spinal Anesthesia With Spinal Opiate. Not yet recruiting NCT03165123 Phase 4 Oral Azithromycin tablet;Intravenous dexamethasone
31 Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery Terminated NCT00839488 Phase 4 pantoprazole 40 mg iv;famotidine 20 mg iv
32 A Prospective, Randomized, Double-Blind Protocol to Compare the Efficacy of Lansoprazole to Ranitidine in Healing Pre-Existing and/or Preventing the Development of Gastroduodenal Stress Ulceration and Postoperative Bleeding in Patients Undergoing Elective Coronary Artery Bypass Graft or Cardiac Valve Replacement Surgery Terminated NCT00220909 Phase 4 Lansoprazole
33 Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) Terminated NCT02825342 Phase 4 Citalopram
34 Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Withdrawn NCT03038009 Phase 4 Pantoprazole
35 Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
36 The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin Unknown status NCT00281047 Phase 2, Phase 3 FP-10
37 Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1% Unknown status NCT02068859 Phase 3 Diclofenac Cream 8%;Diclofenac Gel 1%
38 Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
39 A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Daily NSAID is Continued Completed NCT00401752 Phase 3 Esomeprazole;Ranitidine
40 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Completed NCT00961350 Phase 3 PA32540;EC Aspirin 325
41 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Completed NCT00960869 Phase 3 PA32540;EC-Aspirin 325 mg
42 6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT00527787 Phase 3 PN400 (VIMOVO);Naproxen
43 6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT01129011 Phase 3 PN400 (VIMOVO);Naproxen
44 Phase III Study of a Double-Blind Randomized Comparison of Famotidine Plus Celecoxib Versus Dologesics for Gastric Ulcer Healing in Arthritis Patients (NSAID#5A Study) Completed NCT00153673 Phase 3 celecoxib;Dologesics
45 A Comparative Efficacy and Safety Study of Nexium (Esomeprazole Magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629512 Phase 3 Esomeprazole;Esomeprazole;Placebo
46 A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates Completed NCT01063920 Phase 2, Phase 3 LT-NS001;Naprosyn®
47 A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629928 Phase 3 Esomeprazole;Esomeprazole;Placebo
48 A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 in Subjects Who Are at Risk for Developing NSAID-associated Ulcers Completed NCT00527904 Phase 3 PN400 (VIMOVO);PN 400 (VIMOVO)
49 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- Completed NCT01398410 Phase 2, Phase 3 Rabeprazole;Rabeprazole
50 A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Completed NCT00367211 Phase 3 PN 200 tablets (500 mg naproxen and 20 mg omeprazole);Naproxen 500 mg tablets (PN 200 minus omeprazole)

Search NIH Clinical Center for Gastric Ulcer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
Atropine
Atropine Sulfate
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cat's Claw preparation
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Famotidine
lansoprazole
magaldrate
Magnesium Hydroxide
Methylatropine nitrate
MILK OF MAGNESIA
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Sucralfate

Cochrane evidence based reviews: stomach ulcer

Genetic Tests for Gastric Ulcer

Anatomical Context for Gastric Ulcer

MalaCards organs/tissues related to Gastric Ulcer:

40
Liver, Testes, Bone, Colon, Heart, Pancreas, Lung

Publications for Gastric Ulcer

Articles related to Gastric Ulcer:

(show top 50) (show all 10472)
# Title Authors PMID Year
1
Expression of cyclooxygenase isoforms in ulcerated tissues of the nonglandular portion of the stomach in horses. 54 61
20433387 2010
2
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 54 61
19930551 2009
3
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 54 61
18612816 2009
4
The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. 54 61
19120912 2008
5
The prevalence of cagA and cagE genes in Helicobacter pylori strains isolated from different patient groups by polymerase chain reaction. 54 61
19260336 2008
6
Gene therapy for gastric diseases. 54 61
18537593 2008
7
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. 54 61
17934843 2008
8
Effects of Helicobacter pylori Infection on gastric mucin expression. 54 61
18097286 2008
9
[Expression of hepatocyte growth factor and its receptor in gastric cancer]. 54 61
18024311 2007
10
[The choice of selective COX-2 inhibitors]. 54 61
17926530 2007
11
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer]. 54 61
17717918 2007
12
Restriction fragment length polymorphism of virulence genes cagA, vacA and ureAB of Helicobacter pylori strains isolated from Iranian patients with gastric ulcer and nonulcer disease. 54 61
17457472 2007
13
Helicobacter pylori cagA, vacA and iceA genotypes in northern Thai patients with gastric disease. 54 61
17539287 2007
14
Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. 54 61
17380018 2007
15
Molecular forms of trefoil factor 1 in normal gastric mucosa and its expression in normal and abnormal gastric tissues. 54 61
17143957 2006
16
Influence of COX-2 and local cytokine expressions in gastric ulcer mucosa by H. pylori and NSAID. 54 61
17086892 2006
17
Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts. 54 61
16357062 2006
18
Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer. 54 61
16718800 2006
19
Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: towards a better non-steroidal anti-inflammatory drug. 54 61
16375889 2006
20
[Importance of IgG anti-CagA antibodies of Helicobacter pylori in Venezuelan patients with gastric diseases]. 54 61
16353543 2005
21
Recent advances in gastric ulcer therapeutics. 54 61
16188503 2005
22
Protective role of heat shock protein 27 in gastric mucosal injury. 54 61
16041694 2005
23
The role of cyclooxygenase in gastric mucosal protection. 54 61
16184416 2005
24
Roles of platelets and proteinase-activated receptors in gastric ulcer healing. 54 61
16184414 2005
25
Cellular and molecular mechanisms of gastrointestinal ulcer healing. 54 61
16184417 2005
26
[Association of trefoil factor 1 expression with gastric mucosa injuries and gastric cancer]. 54 61
16174594 2005
27
Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. 54 61
15849833 2005
28
Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa. 54 61
15720413 2005
29
Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. 54 61
15531909 2005
30
Topographic expression of MUC5AC and MUC6 in the gastric mucosa infected by Helicobacter pylori and in associated diseases. 54 61
16325508 2005
31
Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs. 54 61
15213313 2004
32
Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. 54 61
15246970 2004
33
Serum response factor promotes re-epithelialization and muscular structure restoration during gastric ulcer healing. 54 61
15188176 2004
34
Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers. 54 61
15086596 2004
35
[The expression of trefoil factor 1 and trefoil factor 2 in gastric cancer and precancer]. 54 61
15059374 2004
36
Gastric restitution is inhibited by dexamethasone, which is reversed by hepatocyte growth factor and rebamipide. 54 61
12925150 2003
37
Acceleration of gastric ulcer healing by omeprazole in portal hypertensive rats. Is its action mediated by gastrin release and the stimulation of epithelial proliferation? 54 61
12679615 2003
38
Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. 54 61
12678329 2003
39
Relationship between gastric disease and deletion of cag pathogenicity island genes of Helicobacter pylori in gastric juice. 54 61
12645789 2003
40
COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. 54 61
14529402 2003
41
Mucosal repair and COX-2 inhibition. 54 61
14529401 2003
42
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. 54 61
12232050 2002
43
Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. 54 61
12217640 2002
44
[Seroprevalence of antibodies against Helicobacter pylori CagA antigen in patients with gastric ulcer in the North region of Brazil]. 54 61
12170324 2002
45
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. 54 61
11943947 2002
46
Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. 54 61
11677194 2001
47
Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. 54 61
11519793 2001
48
[Basal concentrations of gastrin and pepsinogen I and II in gastric ulcer: influence of Helicobacter pylori infection and usefulness in the control of the eradication]. 54 61
11247290 2001
49
Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. 54 61
11252403 2001
50
Consensus and variable region PCR analysis of Helicobacter pylori 3' region of cagA gene in isolates from individuals with or without peptic ulcer. 54 61
11158115 2001

Variations for Gastric Ulcer

Expression for Gastric Ulcer

Search GEO for disease gene expression data for Gastric Ulcer.

Pathways for Gastric Ulcer

Pathways related to Gastric Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 VEGFA TNF PTGS2 IL6 IL1B HGF
2
Show member pathways
13.56 VEGFA TNF IL6 IL1B HGF FGF2
3
Show member pathways
13.32 TNF IL6 IL1B HGF FGF2 EGF
4
Show member pathways
13.32 VEGFA TNF PTGS2 IL6 IL1RN IL1B
5
Show member pathways
13.01 VEGFA TNF PTGS2 IL6 HGF FGF2
6
Show member pathways
12.96 VEGFA TNF PTGS2 IL6 IL1B FGF2
7 12.86 VEGFA PTGS2 IL6 HGF FGF2 EGF
8 12.79 VEGFA TNF IL1B HGF FGF2 EGF
9
Show member pathways
12.74 TNF IL6 IL1B HGF FGF2 EGF
10
Show member pathways
12.64 VEGFA IL6 HGF FGF2 EGF
11 12.59 TNF PTGS2 PTGS1 IL1RN IL1B
12
Show member pathways
12.37 TNF PTGS2 PTGS1 IL6 IL1B
13
Show member pathways
12.34 TFF1 PTGS2 HRH2 EGF
14
Show member pathways
12.34 TNF S100A8 PTGS2 IL6 IL1B CXCL8
15
Show member pathways
12.33 TNF PTGS2 IL6 IL1B FGF2 CXCL8
16 12.32 VEGFA TNF HGF FGF2
17 12.31 TNF IL6 IL1B CXCL8
18
Show member pathways
12.3 TNF IL6 IL1B HGF FGF2 CXCL8
19 12.26 TNF IL6 IL1B CXCL8
20
Show member pathways
12.24 TNF PTGS2 IL6 IL1B
21 12.23 VEGFA TNF PTGS2 IL6 EGF
22
Show member pathways
12.22 TNF IL6 IL1B CXCL8
23
Show member pathways
12.2 TNF PTGS2 IL6 IL1RN IL1B CXCL8
24 12.12 VEGFA TNF SST IL6 IL1RN IL1B
25 12.1 VEGFA IL6 HGF FGF2 EGF
26 12.05 TNF IL6 IL1B CXCL8
27 12.02 TNF PTGS2 IL6 IL1B CXCL8
28 12.01 TNF PTGS2 IL6 IL1B
29 11.96 TNF PTGS2 IL1B CXCL8
30 11.96 TNF IL6 IL1B CXCL8
31 11.93 VEGFA TNF IL6 IL1B CXCL8
32 11.86 VEGFA TNF IL6 IL1B CXCL8
33 11.81 TNF IL6 IL1B CXCL8
34 11.8 IL6 IL1B CXCL8
35 11.8 VEGFA FGF2 EGF
36
Show member pathways
11.78 TNF PTGS2 CXCL8
37 11.76 TNF IL6 IL1B
38 11.76 VEGFA EGF CXCL8
39 11.71 TNF PTGS2 IL6 IL1RN IL1B
40 11.66 TNF IL6 IL1B CXCL8
41 11.64 VEGFA PTGS2 PTGS1
42 11.61 VEGFA TNF PTGS2 IL6 IL1B HGF
43
Show member pathways
11.6 VEGFA TNF PTGS2 IL6 IL1B CXCL8
44 11.59 VEGFA PTGS2 IL6 CXCL8
45 11.55 VEGFA TNF PTGS2
46 11.53 TNF IL6 IL1B HGF CXCL8
47 11.52 TNF IL6 IL1B CALCA
48 11.5 VEGFA FGF2 EGF
49
Show member pathways
11.48 VEGFA HGF EGF
50 11.48 VEGFA IL6 HGF FGF2 EGF

GO Terms for Gastric Ulcer

Cellular components related to Gastric Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 VEGFA TNF TFF1 SST S100A8 PSCA
2 extracellular space GO:0005615 9.47 VEGFA TNF TFF1 SST S100A8 IL6
3 platelet alpha granule lumen GO:0031093 9.33 VEGFA HGF EGF

Biological processes related to Gastric Ulcer according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 VEGFA TFF1 IL6 IL1RN IL1B HRH2
2 positive regulation of cell proliferation GO:0008284 10.09 VEGFA PTGS2 IL6 IL1B FGF2 EGF
3 positive regulation of gene expression GO:0010628 10.08 VEGFA TNF IL6 IL1B EGF
4 immune response GO:0006955 10.08 TNF IL6 IL1RN IL1B HRH2 CXCL8
5 negative regulation of cell proliferation GO:0008285 10.03 TFF1 SST PTGS2 IL6 IL1B CXCL8
6 positive regulation of protein phosphorylation GO:0001934 9.97 VEGFA TNF IL1B HGF
7 MAPK cascade GO:0000165 9.97 TNF IL1B HGF FGF2 EGF
8 angiogenesis GO:0001525 9.97 VEGFA PTGS2 FGF2 EGF CXCL8
9 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF HGF FGF2 EGF
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.94 TNF S100A8 IL6 IL1B
11 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 IL1RN IL1B CXCL8
12 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.87 VEGFA PTGS2 HGF
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 VEGFA TNF IL6
14 regulation of blood pressure GO:0008217 9.85 PTGS2 PTGS1 CALCA
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF PTGS2 IL6
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 VEGFA IL6 HGF EGF
17 positive chemotaxis GO:0050918 9.83 VEGFA HGF FGF2
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 VEGFA TNF PTGS2 IL6
19 positive regulation of cell division GO:0051781 9.82 VEGFA IL1B FGF2
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 TNF PTGS2 IL1B
21 neutrophil chemotaxis GO:0030593 9.81 S100A8 IL1RN IL1B CXCL8
22 embryo implantation GO:0007566 9.8 PTGS2 IL1B CALCA
23 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.8 VEGFA PTGS2 FGF2
24 positive regulation of vascular endothelial growth factor production GO:0010575 9.77 PTGS2 IL6 IL1B
25 negative regulation of neurogenesis GO:0050768 9.77 TNF IL6 IL1B
26 positive regulation of interleukin-8 production GO:0032757 9.76 TNF IL1B CALCA
27 response to glucocorticoid GO:0051384 9.76 TNF PTGS2 IL6 IL1RN
28 positive regulation of MAP kinase activity GO:0043406 9.73 VEGFA TNF FGF2 EGF
29 positive regulation of angiogenesis GO:0045766 9.72 VEGFA IL1B HGF FGF2 CXCL8
30 positive regulation of interleukin-6 production GO:0032755 9.71 TNF IL6 IL1RN IL1B
31 positive regulation of chemokine biosynthetic process GO:0045080 9.7 TNF IL1B
32 cyclooxygenase pathway GO:0019371 9.7 PTGS2 PTGS1
33 regulation of neuroinflammatory response GO:0150077 9.69 PTGS2 IL6
34 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
35 regulation of establishment of endothelial barrier GO:1903140 9.67 TNF IL1B
36 positive regulation of prostaglandin biosynthetic process GO:0031394 9.67 PTGS2 IL1B
37 positive regulation of glial cell proliferation GO:0060252 9.67 TNF IL6 IL1B
38 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.65 IL6 IL1RN
39 negative regulation of smooth muscle contraction GO:0045986 9.65 PTGS2 CALCA
40 activation of MAPK activity GO:0000187 9.65 TNF IL1B HGF FGF2 EGF
41 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IL1B
43 inflammatory response GO:0006954 9.61 TNF S100A8 PTGS2 PTGS1 IL6 IL1RN
44 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
45 positive regulation of fever generation GO:0031622 9.33 TNF PTGS2 IL1B
46 cytokine-mediated signaling pathway GO:0019221 9.28 VEGFA TNF PTGS2 IL6 IL1RN IL1B

Molecular functions related to Gastric Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.43 VEGFA HGF FGF2
2 growth factor activity GO:0008083 9.43 VEGFA TFF1 IL6 HGF FGF2 EGF
3 cytokine activity GO:0005125 9.17 VEGFA TNF IL6 IL1RN IL1B FGF2
4 prostaglandin-endoperoxide synthase activity GO:0004666 9.16 PTGS2 PTGS1

Sources for Gastric Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....